Specificity of HercepTest in Determining HER-2/neu Status of Breast Cancers Using the United States Food and Drug Administration–Approved Scoring System
- 1 July 1999
- journal article
- rapid publications
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 17 (7), 1983
- https://doi.org/10.1200/jco.1999.17.7.1983
Abstract
PURPOSE: To evaluate the specificity of the HercepTest for Immunoenzymatic Staining (Dako Corp, Carpinteria, CA) for determining HER-2/neu protein expression in breast cancer. MATERIALS AND METHODS...Keywords
This publication has 21 references indexed in Scilit:
- Should Selection of Adjuvant Chemotherapy for Patients With Breast Cancer Be Based on erbB-2 Status?JNCI Journal of the National Cancer Institute, 1998
- C-erbB-2 immunostaining: problems with interpretation.Journal of Clinical Pathology, 1994
- ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancerCancer Letters, 1994
- c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast CancerNew England Journal of Medicine, 1994
- Analysis of cerbB2 expression using a panel of 6 commercially available antibodiesPathology, 1994
- Detection of c-erbB-2 activation in paraffin-embedded tissue by immunohistochemistryHuman Pathology, 1992
- ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization.Proceedings of the National Academy of Sciences, 1992
- Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancerBritish Journal of Cancer, 1992
- pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐upHistopathology, 1991
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987